Literature DB >> 12672819

The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappa B.

Yoshiharu Higuchi1, Kinya Otsu, Kazuhiko Nishida, Shinichi Hirotani, Hiroyuki Nakayama, Osamu Yamaguchi, Shungo Hikoso, Kazunori Kashiwase, Toshihiro Takeda, Tetsuya Watanabe, Toshiaki Mano, Yasushi Matsumura, Hikaru Ueno, Masatsugu Hori.   

Abstract

The small guanine nucleotide-binding protein Rac1 has emerged as an important molecule involved in cardiac myocyte hypertrophy. Recently, we reported on apoptosis signal-regulating kinase (ASK) 1 and a transcriptional factor, nuclear factor-kappaB (NF-kappaB), as novel signaling intermediates in cardiac myocyte hypertrophy. The aim of the study presented here was to clarify the role of Rac1 in the ASK1-NF-kappaB signaling pathway. Infection of isolated neonatal cardiac myocytes with an adenovirus expressing a constitutively active form of Rac1 (RacV12) enhanced the expression of a kappaB-dependent reporter gene construct and induced the degradation of IkappaBalpha. Expression of a degradation-resistant mutant of IkappaBalpha inhibited the RacV12-induced hypertrophic responses, including increases in protein synthesis and atrial natriuretic factor production and the enhancement of sarcomeric organization. An immune complex kinase assay indicated that the expression of RacV12 activated ASK1. Expression of a dominant negative mutant of ASK1 eliminated the RacV12-induced NF-kappaB activation and the biochemical and morphological hypertrophic responses, whereas expression of a dominant negative form of Rac1 attenuated phenylephrine-induced activation of ASK1 and NF-kappaB and cardiac myocyte hypertrophy. These findings suggest that Rac1 induces cardiac myocyte hypertrophy mediated through ASK1 and NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672819     DOI: 10.1074/jbc.M213203200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  S-nitrosylation: physiological regulation of NF-kappaB.

Authors:  Harvey E Marshall; Douglas T Hess; Jonathan S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-08       Impact factor: 11.205

Review 2.  NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology.

Authors:  Alison Cave; David Grieve; Sofian Johar; Min Zhang; Ajay M Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

3.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

4.  Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B Axis.

Authors:  Dongfang Yang; Jia Yuan; Gan Liu; Zhiyu Ling; Haiyan Zeng; Yunqing Chen; Yue Zhang; Qiang She; Xue Zhou
Journal:  Int J Med Sci       Date:  2013-04-26       Impact factor: 3.738

5.  Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.

Authors:  Huey-Jiun Li; Hang Yin; Yu-Yu Yao; Bo Shen; Michael Bader; Lee Chao; Julie Chao
Journal:  Cardiovasc Res       Date:  2006-10-27       Impact factor: 10.787

6.  Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.

Authors:  Juliette Nectoux; Yann Fichou; Nicolas Cagnard; Nadia Bahi-Buisson; Patrick Nusbaum; Franck Letourneur; Jamel Chelly; Thierry Bienvenu
Journal:  J Mol Med (Berl)       Date:  2010-11-24       Impact factor: 4.599

Review 7.  The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox.

Authors:  Demetrios Moris; Michael Spartalis; Eleftherios Spartalis; Georgia-Sofia Karachaliou; Georgios I Karaolanis; Gerasimos Tsourouflis; Diamantis I Tsilimigras; Eleni Tzatzaki; Stamatios Theocharis
Journal:  Ann Transl Med       Date:  2017-08

8.  Requirement of Rac1 in the development of cardiac hypertrophy.

Authors:  Minoru Satoh; Hisakazu Ogita; Kyosuke Takeshita; Yasushi Mukai; David J Kwiatkowski; James K Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Rad GTPase deficiency leads to cardiac hypertrophy.

Authors:  Lin Chang; Jifeng Zhang; Yu-Hua Tseng; Chang-Qing Xie; Jacob Ilany; Jens C Brüning; Zhongcui Sun; Xiaojun Zhu; Taixing Cui; Keith A Youker; Qinglin Yang; Sharlene M Day; C Ronald Kahn; Y Eugene Chen
Journal:  Circulation       Date:  2007-12-03       Impact factor: 29.690

Review 10.  Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.

Authors:  Qian Zhou; James K Liao
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.